Sandoz Expects ‘Trough Year’ In 2023 As It Counts Cost Of Spinoff
Novartis Management Outlines Path Ahead For Sandoz As It Prepares To Separate
Sandoz is set for a “trough year” in 2023 as the generics and biosimilars unit faces costs linked with its spinoff from parent company Novartis that will erode its core operating income.
